The Top Telehealth Services Providers Should Add on in 2026 (to Grow Faster & Upsell Smarter)
Drive new revenue, extend LTV, and elevate patient care—while keeping ops lean.
The biggest growth levers right now: GLP-1s, TRT, HRT, longevity meds (Sermorelin, NAD+), whole-health testing + supplements, premade meals, and 24/7 urgent care. Below you’ll find market size snapshots and exactly what to look for in a partner so you can plug in services fast, compliantly, and at scale.
GLP-1 Programs (weight management & cardiometabolic)
Why this market: Obesity remains widespread—23 U.S. states have adult obesity ≥35%. Analysts estimate the GLP-1 weight-loss market at ~$13.8B in 2024 to ~$48.8B by 2030, and broader forecasts peg total GLP-1 sales at >$100B by 2030. Coverage is expanding:
What to look for in a GLP-1 provider:
Clinician network that scales nationally with fast SLAs.
Strong pricing + inventory with a diversified supply chain.
Versatile delivery options such as injections, orals, and the StatRx liposomal formulations.
Microdosing options to help patients with unique needs achieve their goals.
TRT — Testosterone Replacement Therapy
Why this market: The global TRT market was ~$1.9B in 2024. Demand is increasing and many believe the market is underserved. In fact, 40% of men aged under 40 years have expressed interest in Testosterone Replacement Therapy while only 14% are using or have previously used TRT. From 2018 to 2022, the usage of TRT increased across all age demographics:
≤24 years increased by 120%
25–34 years increased by 86%
35–44 years increased by 45%
45-54 years increased by 35%
55–64 year increased by 17
≥65 years increased by 12% Source: US Pharmacist
What to look for (your focus):
Clinician network that scales nationally with fast SLAs.
Strong lab pricing + systems to help ensure patients have a successful experience getting started with TRT.
Multiple delivery formats such as injections + the StatRx liposomal formulation.
Ability to offer Longevity bundling options such as Sermorelin and NAD+.
HRT - Hormone Replacement Therapy
Why this market: The global HRT market was ~$23.6B in 2024 and is projected to reach ~$39.4B by 2033 (other estimates: ~$27.5B by 2032). Demand is expanding online as menopause and GAHT services normalize.
What to look for in an HRT provider:
Scale-ready clinician bench across all 50 states.
Strong lab pricing + systems to help ensure patients have a successful experience getting started with HRT.
Delivery flexibility including gels and the StatRx liposomal formulation
The ability to offer competitive GLP-1 programs as there is a strong demographic overlap between HRT and GLP-1 patients.
Longevity Medications (Sermorelin, NAD+)
Why this market: “Healthspan” add-ons often sell well alongside GLP-1/TRT. Peptide therapeutics were ~$117.3B in 2024 with ~10.8% CAGR to 2030. The NAD+ IV niche was ~$281–289M in 2023 and is forecast ~$449–458M by 2030 (≈7–8% CAGR).
What to look for in a Longevity Provider:
Formulary breadth + bundle pricing with TRT/GLP-1/supplements to potentially lift customer lifetime value (LTV).
Delivery innovation such as injections and the StatRx liposomal formulation.
Whole-Health Testing + Supplements
Why this market: The direct-to-consumer lab testing market is ~$3.44B (2024) to ~$8.07B by 2034. On the retail side, the U.S. protein supplements market is ~$10.5B (2024) to ~$24.2B by 2034; global creatine supplements are ~$1.11B (2024) to ~$4.21B by 2030; and weight-loss supplements are ~$33.1B (2024) to ~$71.6B by 2030.
What to look for in a whole-health testing provider:
Actionable pathways and offerings from results (medication/supplement/meal-plan options that patients can decide to use to achieve their goals. You don’t just want to provide the data - you want to be a piece of solving their challenges.
Patient-friendly mobile app (clear visuals, education, ease of use)
A large clinician network to help interpret results and, when medically appropriate, discuss options.
The ability to offer supplements at competitive price points for patients to take control of their health based on their results.
Premade & Medically Informed Meals (nutrition that multiplies outcomes)
Why this market: The U.S. meal-kit market was ~$10.4B in 2023 and is growing ~10–11% CAGR through 2030. Medically tailored meals show real health-economic value—national adoption could avert ~1.6M hospitalizations and net ~$13.6B in annual savings.
What to look for in a premade meal provider:
Nutrition specifically designed to align with goals of people on medication pathways such as GLP-1s.
Cost-competitive, rotating menus with macro/micro targets.
Easy upsells (bundle in the same checkout; subscriptions).
24/7 Virtual Urgent Care
Why this market: This is a high-intent entry point and cross-sell engine. The virtual urgent care market is projected ~$7.5B (2025) to ~$16.8B by 2032, and the brick-and-mortar footprint is huge (~14,245 U.S. urgent care centers (Sept 2024)) creating hybrid referral paths.
What to look for (your focus):
Versatile clinician network that can see patients fast, any time.
Deep add-on catalog from one provider (meds, supplements, testing, meals).
Why Brands Choose OpenLoop to Launch New Telehealth Services
Plug in what you need. Scale when you’re ready. OpenLoop is the top white-label digital health infrastructure provider. You control your brand—we power everything behind the scenes. Launch faster, scale nationwide, and deliver smarter care.
An expansive set of offerings including GLP-1s, TRT, HRT, Longevity, Whole-Health Testing, Premade Meals, Supplements, Urgent Care, and much more.
Fully managed staffing with one of the nation’s largest and highest rated telehealth clinician networks.
Robust legal, financial & compliance support.
Seamless EHR integrations and nationwide payer coverage.
24/7/365 patient support and strong TrustPilot reviews
You focus on your brand. OpenLoop handles the rest.
*This content is intended for general informational purposes only and should not be construed as legal advice. For guidance on your specific situation, please consult a licensed attorney. *Compounded drug products are not FDA approved. FDA does not evaluate compounded products for safety, effectiveness, or quality. Prescription products require an online consultation with a healthcare provider who will determine if a prescription is appropriate. Not available in all 50 states.
*This content is intended for general informational purposes only and should not be construed as legal advice. For guidance on your specific situation, please consult a licensed attorney.